PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis
Phase of Trial: Phase 0
Latest Information Update: 18 Jan 2019
Price : $35 *
At a glance
- Drugs Alirocumab (Primary)
- Indications Atherosclerosis; Cerebrovascular disorders
- Focus Therapeutic Use
- 09 Jan 2019 Status changed from not yet recruiting to recruiting.
- 22 Aug 2018 Planned initiation date changed from 1 Jun 2018 to 1 Oct 2018.
- 27 Apr 2018 New trial record